Despite the failure of Eli Lilly's anti-amyloid antibody solanezumab in its latest phase III trial for Alzheimer disease, a bulging pipeline of amyloid-modulating candidates and novel clinical trial strategies still hold promise.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Mullard, A. Alzheimer amyloid hypothesis lives on. Nat Rev Drug Discov 16, 3–5 (2017). https://doi.org/10.1038/nrd.2016.281
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.281
- Springer Nature Limited
This article is cited by
-
Intermittent hypoxia therapy ameliorates beta-amyloid pathology via TFEB-mediated autophagy in murine Alzheimer's disease
Journal of Neuroinflammation (2023)
-
A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing β-Site Amyloid Precursor Protein Cleaving Enzyme 1’s Expression and H2O2-Induced Cytotoxicity in SH-SY5Y Cells
Neurochemical Research (2020)
-
Ocular amyloid imaging at the crossroad of Alzheimer’s disease and age-related macular degeneration: implications for diagnosis and therapy
Journal of Neurology (2019)
-
Neuroprotective effect of naturally occurring RXR agonists isolated from Sophora tonkinensis Gagnep. on amyloid-β-induced cytotoxicity in PC12 cells
Journal of Natural Medicines (2019)
-
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Scientific Reports (2018)